

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6595372

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST	
CONVEYING PARTY DATA		
Name		Execution Date
SETH LEHR		03/09/2021
RECEIVING PARTY DATA		
Name:	CONTEXT BIOPHARMA, INC.	
Street Address:	3675 MARKET STREET	
Internal Address:	SUITE 200	
City:	PHILADELPHIA	
State/Country:	PENNSYLVANIA	
Postal Code:	19104	
PROPERTY NUMBERS Total: 19		
Property Type	Number	
Patent Number:	9193757	
Patent Number:	10308676	
Patent Number:	10548905	
Application Number:	14942809	
Application Number:	15464085	
Application Number:	15825697	
Application Number:	16720425	
Application Number:	61777752	
Application Number:	62080868	
Application Number:	62233166	
Application Number:	62267540	
Application Number:	62310944	
Application Number:	62428401	
PCT Number:	US2014023651	
PCT Number:	US2015060940	
PCT Number:	US2016053435	
PCT Number:	US2016066420	
PCT Number:	US2017023256	
PCT Number:	US2017063638	

PATENT

CORRESPONDENCE DATA**Fax Number:** (215)988-2757

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: karen.spina@faegredrinker.com**Correspondent Name:** ROBERT E. CANNUSCIO**Address Line 1:** ONE LOGAN SQUARE, STE. 2000**Address Line 2:** FAEGRE DRINKER BIDDLE & REATH LLP**Address Line 4:** PHILADELPHIA, PENNSYLVANIA 19103-6996

ATTORNEY DOCKET NUMBER:	221757-595023
--------------------------------	---------------

NAME OF SUBMITTER:	KAREN M. SPINA
---------------------------	----------------

SIGNATURE:	/Karen M. Spina/
-------------------	------------------

DATE SIGNED:	03/11/2021
---------------------	------------

Total Attachments: 4

source=Context_-_Release_of_IP_Security_Interest#page1.tif

source=Context_-_Release_of_IP_Security_Interest#page2.tif

source=Context_-_Release_of_IP_Security_Interest#page3.tif

source=Context_-_Release_of_IP_Security_Interest#page4.tif

RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST

THIS RELEASE OF INTELLECTUAL SECURITY INTEREST (this “**Release**”) is effective as of March 9, 2021 (the “**Effective Date**”), by and between Context BioPharma, Inc., a Delaware corporation (“**Context BioPharma**”), and Seth Lehr in his capacity as Collateral Agent and for the benefit of the Secured Parties under the Security referred to below (in such capacity, together with any successor thereto in such capacity, the “**Collateral Agent**”).

WHEREAS, the parties hereto previously entered into a certain Amendment, Guaranty and Joinder to Security Agreement dated April 1, 2020 (the “**Security Agreement**”) pursuant to which Context BioPharma agreed to grant a continuing security interest in, among other things, all Intellectual Property Collateral (as defined in a certain Grant of Intellectual Property Security Interest dated April 1, 2020, the “**Security Interest**”) to secure the Secured Obligations (as defined in the Security Agreement);

WHEREAS, the Security Interest was recorded with the United States Patent and Trademark Office on 04/02/2020 at Reel Frame 052293/0109 against the intellectual property set forth in **Schedule A**; and

WHEREAS, Debtor has fulfilled all its obligations owed to the Secured Parties and Collateral Agent, and the Secured Parties and Collateral Agent wish to acknowledge and confirm the release of all security interests held by the Secured Parties and Collateral Agent in Context BioPharma’s intellectual property, including the intellectual property set forth in Schedule A secured under the Security Interest.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the Secured Parties by and through Collateral Agent do hereby acknowledge and confirm the release all of their security interests in and to all of Context BioPharma’s intellectual property, including the intellectual property set forth in Schedule A, and discharge, quit claim, relinquish and re-assign to Context BioPharma and any party that has rights under such intellectual property (in each case without recourse and without any representation or warranty) any and all rights, title and interest it has in, to and under such intellectual property, effective as of the Effective Date.


[Signature Page Follows]

IN WITNESS WHEREOF, the parties have caused this Release of Intellectual Property Security Interest to be duly executed as of the date set forth below.

CONTEXT BIOPHARMA, INC.

By: 
7029AE2F2341488...
Name: Martin Lehr
Title: Chief Executive Officer
Date: 03/10/21

SETH LEHR, Collateral Agent

By: 
Name: Seth Lehr
Date: 3/10/21

SCHEDULE A

Application No.	Country	Filing Date	Patent No. or Status
ONAPRISTONE POLYMORPHIC FORMS AND METHODS OF USE			
61/777752	US	03/12/2013	Provisional
14/203814	US	03/11/2014	Patent granted US 9193757 issued on 11/24/2015
PCT/US2014/023651	PCT	03/11/2014	Inactive
2018-090510	Japan Div		Pending
2014248928	Australia	03/11/2014	Patent granted AU 2014248928 issued on 03/21/2019
2904116	Canada	03/11/2014	Pending
201480014329.1	China	03/11/2014	Reviving in process
161063905	Hong Kong	03/11/2014	Pending
1020157027542	Korea	03/11/2014	Pending
Mexico/a/2015012142	Mexico	03/11/2014	Pending
Mexico/a/2017014044	Mexico Div	03/11/2014	Pending
ONAPRISTONE EXTENDED-RELEASE COMPOSITIONS AND METHODS			
62/080868	US	11/17/2014	Provisional
14/942809	US	11/16/2015	Pending
PCT/US2015/060940	PCT	11/16/2015	Inactive
15861014.7	Europe	11/16/2015	Pending
2966753	Canada	11/16/2015	Pending
18106169.2	Hong Kong	11/16/2015	Pending
2015350241	Australia	11/16/2015	Pending
201580062192.1	China	11/16/2015	Pending
2017-520520	Japan	11/16/2015	Patent Granted on 01/07/2020 To be issued.
1020177012909	Korea	11/16/2015	Pending
MX/A/2017/005163	Mexico	11/16/2015	Pending
AMORPHOUS ONAPRISTONE COMPOSITIONS AND METHODS OF MAKING THE SAME			
62/267540	US	12/15/2015	Provisional
15/378004	US	12/13/2016	Patent granted US 10548905 issued on 02/04/2020
16/720425	US	12/19/2019	Pending
PCT/US2016/066420	PCT	12/13/2016	Inactive
2016370499	Australia	12/13/2016	Pending
3008422	Canada	12/13/2016	Pending

Application No.	Country	Filing Date	Patent No. or Status
201680077010.2	China	12/13/2016	Pending
16876503.0	Europe	12/13/2016	Pending
201817022508	India	12/13/2016	Pending
10-2018-7019175	Korea	12/13/2016	Pending
Mx/a/2018/007154	Mexico	12/13/2016	Pending
18115767.9	Hong Kong	12/10/2018	Pending
18114258.8	Hong Kong	11/08/2018	Pending
ONAPRISTONE METABOLITE COMPOSITIONS AND METHODS			
62/310944	US	03/21/2016	Provisional
15/464085	US	03/20/2017	Pending
PCT/US2017/023256	PCT	03/20/2017	Inactive
2018-549568	Japan	03/20/2017	Pending
METHODS OF MAKING ONAPRISTONE INTERMEDIATES			
62/233166	US	09/25/2015	Provisional
15/274555	US	09/23/2016	Patent granted US 10308676 issued on 06/04/2019
PCT/US2016/053435	PCT	09/23/2016	Inactive
2998924	Canada	09/23/2016	Pending
16849747.7	EP	09/23/2016	Pending
BR1120180059994	Brazil	09/23/2016	Pending
2018-509611	Japan	09/23/2016	Pending
2016326657	Australia	09/23/2016	Patent Granted AU 2016326657 issued on 02/06/2020
METHODS FOR ONAPRISTONE SYNTHESIS DEHYDRATION AND DEPROTECTION			
62/428401	US	11/30/2016	Provisional
15/825697	US	11/29/2017	Pending
PCT/US2017/063638	PCT	11/29/2017	Inactive